Menopause: focus on additional therapy opportunities. Literature review


  • О. О. Єфіменко SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine” “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine
  • О. В. Занько State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine



menopause, climacteric syndrome, menopausal metabolic syndrome, menopausal hormone therapy, phytoestrogens, α-lipoic acid, Climona


About 10% of the world's populations are menopausal women. This period coincides with the most active social and professional activities of almost every woman. In addition to typical manifestations, this age stage is characterized by menopausal metabolic syndrome, which is caused by estrogen deficiency and is found in 35–49% of women in older age groups.

Modern approaches to the treatment and prevention of menopausal disorders include following principles: lifestyle changes, menopausal hormone therapy (MHT), non-hormonal therapy (drugs with hormone-like effects, phytoestrogens, selective modulators of estrogen receptors, β-alanine, sedatives, tranquilizers, and antidepressants), non-drug correction methods.

According to the International Menopause Society recommendations (2016), MHT is a gold standard for prevention and treatment of menopausal disorders. However, the choice of MHT as a therapeutic standard is not always unambiguous and acceptable, because hormone therapy is associated with a number of side effects. In addition, there are a number of absolute contraindications for MHT. Therefore, the task of a gynecologist is to choose personalized (individual) therapy for menopausal disorders for each patient. Factors that must be considered when choosing between MHT and non-hormonal drugs include: severity and duration of menopause syndrome, presence of absolute and relative contraindications for MHT, patient’s desire, tolerance of the chosen method.

Phytoestrogens (selective modulators of plant-derived estrogen receptors, which are structurally similar to endogenous estrogens) are well-researched among the means of non-hormonal therapy of menopausal patients. Due to their weak estrogenic action, they reduce the severity of menopausal syndrome without affecting the proliferative processes in the endometrium. Phytoestrogens are used by gynecologists in many countries for mild climacteric complaints and/or if there are absolute contraindications for MHT. One of these drugs is Climona® that is contains biologically active components of plant origin (hop cones, cimicifuga root, dioscorea root, vitamin D, α-lipoic acid), which have been shown to be effective in decrease of menopause manifestations and reducing menopausal metabolic syndrome

Author Biographies

О. О. Єфіменко, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine” “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

PhD, senior researcher at the Endocrine Gynecology Department

Department of Reproductive Health of State Scientific Institution

О. В. Занько, State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

PhD, junior researcher at the Department of Reproductive Health


  1. Gold, E.B., Crawford, S.L., Avis, N.E., et al. “Factors related to age at natural menopause: longitudinal analyses from SWAN.” Am J Epidemiol 178 (2013): 70–83.
  2. Yefimenko, O.A. “Menopausal disorders: focus on the early start of pathogenetic therapy.” Zdorovya Ukrainy. Hinekolohiia. Akusherstvo. Reproduktolohiia 2.30 (2018): 20–1.
  3. Gavisova, A.A., Tverdikova, M.A., Balushkina, A.A. “Menopausal syndrome: features of treatment of psycho-emotional disorders.” Russian Medical Journal 20 (2009): 1408.
  4. Karlamangla, A.S., Lachman, M.E., Han, W., et al. “Evidence for Cognitive Aging in Midlife Women: Study of Women’s Health Across the Nation.” PLoS ONE 12.1 (2017): e0169008. DOI: 10.1371/journal.pone.0169008
  5. Mitchell, E.S., Woods, N.F. “Cognitive symptoms during the menopausal transition and early postmenopause.” Climacteric 14 (2011): 252–61.
  6. de Villiers, T., Tatarchuk, T.F., et al. “National consensus on the management of menopausal patients.” Reproductive endocrinology 1.27 (2016): 8–25. DOI:
  7. Pinkerton, J.V. “Hormone Therapy for Postmenopausal Women.” N Engl J Med 382 (2020): 446–55. DOI: 10.1056/NEJMcp1714787
  8. Manson, J.E., Kaunitz, A.M. “Menopause Management – Getting Clinical Care Back on Track.” N Engl J Med 374 (2016): 803–6. DOI: 10.1056/NEJMp1514242
  9. Takahashi, T.A., Johnson, K.M. “Menopause.” Med Clin North Am 99.3 (2015): 521–34. DOI: 10.1016/j.mcna.2015.01.006
  10. Minkin, M.J. “Menopause: Hormones, Lifestyle, and Optimizing Aging.” Obstet Gynecol Clin North Am 46.3 (2019): 501–14. DOI: 10.1016/j.ogc.2019.04.008
  11. Santoro, N., Epperson, C.N., Mathews, S.B. “Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am 44.3 (2015): 497–515. DOI: 10.1016/j.ecl.2015.05.001
  12. Reid, R., Abramson, B.L., Blake, J., et al.; Menopause and Osteoporosis Working Group. “Managing Menopause.” J Obstet Gynaecol Can 36.9 (2014): 830–3. DOI: 10.1016/S1701-2163(15)30487-4
  13. Edwards, H., Duchesne, A., Au, A.S., Einstein, G. “The Many Menopauses: Searching the Cognitive Research Literature for Menopause Types.” Menopause 26.1 (2019): 45–65. DOI: 10.1097/GME.0000000000001171
  14. Johnson, A., Roberts, L., Elkins, G. “Complementary and Alternative Medicine for Menopause.” J Evid Based Integr Med 24 (2019). DOI: 10.1177/2515690X19829380
  15. Collins Fantasia, H., Sutherland, M.A. “Hormone Therapy for the Management of Menopause Symptoms.” J Obstet Gynecol Neonatal Nurs 43.2 (2014): 226–35. DOI: 10.1111/1552-6909.12282
  16. Smetnik, V.P.; MoH of Russian Federation Working Group. Menopausal hormone therapy and maintaining women's health in mature age. National guideline, 2nd edition. Moscow (2017): 57 p.
  17. Smetnik, V.P., Ilyina, L.M., eds. Management of women in peri- and postmenopausal women: practical recommendations. Moscow. Yaroslavl. Litera LLC (2010): 221 p.
  18. Santen, P.J., Allred, D.C., Androin, S.P., et al. “Postmenopausal hormone therapy: an Endocrine Society Scientific Statement.” J Clin Endocrinol Metab 95 Suppl. 1 (2010): 1–66.
  19. Sturdee, D.W., Pines, A., Archer, D.F., Baber, D.F. “Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health.” J Climacteric 14 (2011): 302–20.
  20. de Villiers, T.J., Pines, A., Panay, N., et al. “Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.” J Climacteric 16 (2013): 316–37.
  21. The American College of Obstetricians and Gynecologists. “ACOG Practice Bulletin No.141: Management of Menopausal Symptoms.” Obstet Gynecol 123 (2014): 202–16.
  22. Kuznetsova, I.V. “Phytoestrogens in treatment of menopausal disorders.” Gynecology 14.6 (2013): 20–3.
  23. Baraboy, V.A. “Soy isoflavones: biological activity and application.” Biotechnology 2.3 (2009): 44–54.
  24. Dikke G.B. “Menopausal syndrome: symptoms and mechanism of occurrence is the key to understanding alternatives to pathogenetic treatment.” Russian Medical Journal 1 (2019): 57–64.
  25. Santoro, N., Epperson, C.N., Mathews, S.B. “Menopausal symptoms and their management.” Endocrinol Metab Clin North Am 44.3 (2015): 497–515. DOI: 10.1016/j.ecl.2015.05.001
  26. Shakeri, F., Taavoni, S., Goushegir, A., Haghani, H. “Effectiveness of red clover in alleviating menopausal symptoms: a 12-week randomized, controlled trial.” Climacteric 18 (2015): 568–73.
  27. Reed, S.D., Lampe, J.W., Qu, C., et al. “Premenopausal vasomotor symptoms in an ethnically diverse population.” Menopause 21 (2014): 153–8. DOI: 10.1097/GME.0b013e3182952228
  28. Vovchek, A. “An alternative approach to correction of menopausal disorders.” Zdorovya Ukrainy. Hinekolohiia. Akusherstvo. Reproduktolohiia 1.33 (2019): 26–7.
  29. Gordeeva, G.D., Tovstanovskaya, V.A., Ter-Tumasova, A.G. “Phytoestrogens and their effect on women‘s health during menopause.” Women's Health 10.126 (2017): 128–31.
  30. Taku, K., Melby, M.K., Kronenberg, F., et al. “Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials.” Menopause 19.7 (2012): 76–90. DOI: 10.1097/gme.0b013e3182410159
  31. Chen, M.N., Lin, C.C., Liu, C. “Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review.” Climacteric 18.2 (2015): 260–9. DOI: 10.3109/13697137.2014.966241
  32. Lethaby, A., Marjoribanks, J., Kronenberg, F., et al. “Phytoestrogens for menopausal vasomotor symptoms.” Cochrane Database Syst Rev 12 (2013): CD001395. DOI: 10.1002/14651858.CD001395.pub4
  33. Keshavarz, Z., Golezar, S., Hajifoghaha, M., Alizadeh, S. “The effect of phytoestrogens on menopause symptoms: A systematic review.” J Isfahan Med Sch 36.477 (2018): 446–59. DOI: 10.22122/jims.v36i477.9503
  34. Komisarenko, Y.I., Mykhalchyshin, G.P. Endocrinology. Textbook for students of higher medical educational institutions of the 4th accreditation level, 5th edition. Vinnytsya. New Book (2020): 536 p.
  35. The Working Group on Metabolic Syndrome, Diabetes, Prediabetes and Cardiovascular Diseases of the Ukrainian Association of Cardiologists and the Ukrainian Association of Endocrinologist. Diagnosis and treatment of metabolic syndrome, diabetes, prediabetes and cardiovascular diseases. Methodical recommendations. Kyiv (2009): 40 p.
  36. Mitchenko, O.I., Romanov, V.Y., Beliaeva, T.V., et al. “Features of arterial hypertension treatment in women with menopausal metabolic syndrome.” Arterial Hypertension Journal 2.22 (2012).
  37. Mychka, V.B., Kuznetsova, I.V., Voichenko, N.A., et al. “Menopausal metabolic syndrome and hormone replacement therapy.” Effective pharmacotherapy. Cardiology and Angiology 2 (2010).
  38. Kalinchenko, S.Y., Vorslov, L.O., Kournikova, I.A., Gadzinva I.V. “A modern look at the possibilities of using alpha lipoic acid.” Effective pharmacotherapy. Urology and Nephrology 1 (2012).
  39. Bolshova, E.V., Malinovskaya, T.N., Muz, V.A. “Thioctic acid for correction of dyslipidoproteinemia in children and adolescents with metabolic syndrome.” Medicine of Ukraine 10/146 (2010).
  40. Chistik, T. “Possibilities of alpha lipoic acid in weight loss and lipid profile correction in patients with obesity and metabolic syndrome.” International journal of endocrinology 6.70 (2015): 62–6.
  41. Bradley, C., Todd, C. “Anti-Obesity and Lipid Lowering Properties of AlphaLipoic Acid.” Journal of Human Nutrition & Food Science 1 (2013): 1008.
  42. Okanović, A., Prnjavorac, B., Jusufović, E., Sejdinović, R. “Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus.” Med Glas (Zenica) 12.2 (2015): 122–7. DOI: 10.17392/798-15
  43. Mokhort, T.V. “Alpha-lipoic acid: multifactorial effect and rationale use in diabetes mellitus.“ Medical News 3 (2011): 67–71.
  44. Berezin, E.A. “Therapeutic potential of alpha-lipoic (thioctic) acid in cardiovascular diseases.” Ukrainian Medical Journal 2.118 (2017): III/IV.
  45. Kucukgoncu, S., Zhou, E., Lucas, K.B., Tek, C. “Alpha-lipoic Acid (ALA) as a Supplementation for Weight Loss: Results From a Meta-Analysis of Randomized Controlled Trials.” Obes Rev 18.5 (2017): 594–601. DOI: 10.1111/obr.12528
  46. Di Tucci, C., Di Feliciantonio, M., Vena, F., et al. “Alpha Lipoic Acid in Obstetrics and Gynecology.” Gynecol Endocrinol 34.9 (2018): 729–33. DOI: 10.1080/09513590.2018.1462320
  47. Sungmi Park, Udayakumar Karunakaran, Nam Ho Jeoung, et al. “Physiological Effect and Therapeutic Application of Alpha Lipoic Acid.” Curr Med Chem 21.32 (2014): 3636–45. DOI: 10.2174/0929867321666140706141806



How to Cite

Єфіменко, О. О., & Занько, О. В. (2020). Menopause: focus on additional therapy opportunities. Literature review. REPRODUCTIVE ENDOCRINOLOGY, (53), 62–68.



Management of menopause

Most read articles by the same author(s)

1 2 > >>